Mihaela Vasile
About Mihaela Vasile
Mihaela Vasile is a Key Account Manager Immuno-Oncology at Bristol Myers Squibb with over a decade of experience in the medical and pharmaceutical industry, including roles in oncology and veterinary medicine.
Title
Key Account Manager Immuno Oncology
Current Company
Currently working at Bristol Myers Squibb as Key Account Manager Immuno-Oncology.
Professional Experience at Amgen
Mihaela Vasile worked at Amgen as Key Account Specialist Oncology from 2019 to 2020, for 1 year. She also served as Senior Biopharmaceutical Representative Oncology in 2019 for 5 months in Bucharest, Romania.
Professional Experience at Servier
Mihaela Vasile worked at Servier as a Medical Representative from 2016 to 2019 for 3 years in Bucharest, Romania.
Professional Experience at Asia Intercom
Prior to her career in the pharmaceutical industry, Mihaela Vasile worked at Asia Intercom as a Medic Veterinar from 2010 to 2016 for 6 years.
Education and Veterinary Expertise
Mihaela Vasile studied at Universitatea de Științe Agronomice și Medicină Veterinară din București, where she achieved a Doctor in Medicina Veterinara from 2010 to 2014. She also completed a Master's program in 'Igiena alimentelor de origine animala si sanatate publica' from 2009 to 2011 and earned a Doctor Medic Veterinar from the same university from 2003 to 2009. Additionally, she accomplished a Veterinary Residency Program at Université de Liège in 2013 for 11 months.
Transition to Pharmaceutical Industry
With over a decade of experience in the medical and pharmaceutical industry, Mihaela Vasile transitioned from veterinary medicine to the pharmaceutical field, displaying versatility in oncology and immuno-oncology roles.
Background in Oncology
Throughout her career, Mihaela Vasile has gained substantial experience in oncology and immuno-oncology, working in various pivotal roles related to these fields.
Background in Veterinary Medicine and Public Health
Mihaela Vasile has a robust background in veterinary medicine and public health, demonstrated by her advanced degrees and initial career roles prior to her transition into the pharmaceutical sector.